Weight-loss drugs linked to rare vision loss: Harvard study

Novo Nordisk (NVO) and Eli Lilly (LLY) shares dip in reaction to a Harvard study that found GLP-1 weight-loss drugs Ozempic and Wegovy could be linked to rare cases of vision loss.

Yahoo Finance health reporter Anjalee Khemlani explains the study's findings.

For more expert insight and the latest market action, click here to watch this full episode of Market Domination.

This post was written by Luke Carberry Mogan.

Video transcript

I want to talk about a different study that's certainly capturing Wall Street's attention today, putting some pressure on the G LP One stock.

Specifically the findings here from a Harvard study.

What can you tell us about this?

Yes.

OK.

So this is an observational study.

So I want to make sure we point that out and it only looked at semaglutide, which we know are the novo nodus G LP one drug.

So this cannot be broadly associated with a these drugs as well.

The reason for the study was just to look at an association with a type of vision loss with use of the GP ones.

Now, if you recall in the past, we've heard many different side effects of these GP ones over the years.

One of them, we recall really starkly was suicide ideation.

They found the FDA and the EU both found no links with the drug.

So this is just another one of those things.

And that was the point the researchers said was just to let people know there has been some thing identified related possibly to this drug and to call for further studies as well.

So that's sort of where we stand on that right now.

All right.

So maybe in the downward pressure that we're seeing in the stock is just a flip here today.

All right, thanks so much.